Photosensitizers are also used in targeted drug delivery, and light activation is used for releasing the drug from the cargo. The PDT is on the verge of bringing another revolutionizing tool to be used in the treatment of glioblastoma, uveal melanoma, bile duct, pancreatic, and many other cancers.

Modulight’s in-vitro and in-vivo product family enables illumination of anything. We make lasers with variety of wavelengths, ranging from 400 to 2000 nm. Thus, we can support the research of all existing photosensitizers.

ML8500 – automated biomedical illumination device – provides targeted illumination for microplates. Each well is automatically and sequentially illuminated with a specific dose, irradiance and wavelength. Environmental parameters, like carbon dioxide content and temperature, can be adjusted. Optional fluorescence monitoring and cell imaging are also available. ML8500 supports various microplates (24/96/384/1536) and petri dishes. Illumination programs can be created remotely, and collecting data from the cloud can be conveniently done from the office – no need to control the illumination at the lab. Cloud connection enables also the remote support, service, and upgrades.

ML7710 is the most versatile oncology laser system for PDT studies, and the same product can be used for in-vitro/vivo studies and clinical therapies (CE mark, FDA approval for some combination therapies). The ML7710 is a cost-effective solution for long-term study plan including pre-clinical and clinical phases – using the same device from first phase studies to clinical tests makes regulatory work faster. The ML7710 is used already in many clinics and in well-known cancer centers worldwide. We provide internet connectivity, remote diagnostics, cloud services, and low-cost upgrades.

Poul Martin Bendix, PhD, Associate Professor at Niels Bohr Institute

Sherri McFarland, PhD, Professor at University of Texas at Arlington (Formerly Professor at The University of North Carolina at Greensboro)